Bioreactors Market to Reach $51.7 Billion by 2035 at 11.1% CAGR | Sartorius, Cytiva, Eppendorf Among Key Players

The global bioreactors market, currently valued at $16.7 billion, will reach $51.7 billion by 2035, advancing at a compound annual growth rate (CAGR) of 11.1% over the forecast period. Surging demand for biologics, the rapid expansion of contract biomanufacturing, and a broad shift toward single-use systems are together rewriting the economics of bioprocessing, making bioreactor capacity one of the most strategically significant assets in the life sciences supply chain.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/bioreactors-market/request-sample.html

Market Overview
Bioreactors are controlled-environment vessels at the core of upstream biomanufacturing. They culture microorganisms, mammalian cells, and plant tissues under precisely regulated conditions of temperature, pH, pressure, and dissolved oxygen to produce a wide range of biologics, from monoclonal antibodies and vaccines to cell therapies, gene therapy vectors, and 3D tissue constructs used in drug discovery. Global installed bioreactor capacity now exceeds 13 million liters, spanning both captive manufacturing sites and contract facilities.

The market's expansion is tightly coupled with the broader biopharmaceutical boom. Over the past two decades, bioprocessing supplies have grown at 12 to 14% annually, a pace few manufacturing segments match. Companies are responding by building dedicated biomanufacturing sites and by outsourcing production to a growing network of over 305 contract development and manufacturing organizations (CDMOs and CMOs). Both pathways demand more bioreactor capacity, and both are accelerating simultaneously.

Recent investments underscore the momentum. In November 2025, LanzaTech secured a €40 million grant from the European Union's Innovation Fund to support an innovative bioreactor project for biotech applications. In January 2025, Biosphere raised $8.8 million in seed funding to commercialize UV-sterilized bioreactors designed to cut costs in biomanufacturing. These are not isolated bets; they reflect a structural build-out of global bioprocessing infrastructure.

Key Growth Drivers
Rising Demand from Biosimilar Manufacturers. Several blockbuster biologics lose patent protection after 2025, including Humira (adalimumab) and Rituxan (rituximab). As biosimilar manufacturers enter these markets, the need for dedicated bioprocessing capacity, including clinical and commercial-scale bioreactors, rises accordingly. Cost-sensitive biosimilar production intensifies the search for more efficient bioreactor configurations.

CMO Expansion Across Biopharmaceutical Modalities. Because biomanufacturing requires substantial capital investment, pharmaceutical companies increasingly outsource production to CMOs and CDMOs. More than 305 biologics contract manufacturers now offer services across a widening range of modalities, and outsourced biopharmaceutical production is projected to grow faster than captive capacity, directly lifting demand for commercial-grade bioreactors.
Growth of Cell and Gene Therapies. Advanced therapy medicinal products (ATMPs), including cell-based therapies and retroviral vectors for gene therapy, require flexible, smaller-batch production environments. Single-use bioreactors are particularly well suited to these modalities, where batch sizes are smaller and the risk of cross-contamination is critical to manage. The approval pipeline for ATMPs continues to expand, widening the addressable market.

Automation and Digital Manufacturing Integration. More than 60% of bioreactor manufacturers now offer fully automated systems. Many of these integrate with Process Analytical Technology (PAT) platforms that enable real-time monitoring of critical process parameters such as dissolved oxygen, pH, and biomass concentration. Cleaning in Place (CIP) and Sterilization in Place (SIP) capabilities have become standard specifications. This shift toward automated, data-connected systems raises both the performance floor and the price point of modern bioreactors.

Sustainability Pressure Driving Single-Use Adoption. Single-use bioreactors reduce water and energy consumption by approximately 45% and cut initial investment costs by around 40% compared to traditional stainless steel systems. Two-thirds of clinical bioproduction processes already use single-use components, and manufacturers such as ABEC and Thermo Fisher continue to scale this technology upward, with ABEC introducing 4,000-L and 6,000-L disposable systems and Thermo Fisher unveiling a 5,000-L disposable bioreactor.

Market Segmentation
By fabrication material, stainless steel bioreactors currently hold the largest revenue share, a position built on decades of proven performance at commercial scale. However, single-use bioreactors are set to record the highest growth rate through 2035, driven by the flexibility they offer multiproduct facilities and their compatibility with emerging biologics such as antibody-drug conjugates and cell therapies. Glass bioreactors serve primarily laboratory and research applications.

By type of bioprocess, batch and fed-batch systems dominate the market and will retain their majority share through the forecast period. Continuous bioprocessing, which integrates sequential production steps to reduce downtime and contamination risk, is growing at a comparatively faster rate. Merck's December 2022 acquisition of Erbi Biosystems, a developer of a 2 mL continuous perfusion cell culture platform scalable to 2,000 L, signals how seriously large players are positioning for this transition. By type of biologic, antibodies generate the highest revenues, reflecting the more than 170 approved therapeutic antibodies and a development pipeline spanning bispecifics, ADCs, and Fc fusion proteins.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/bioreactors-market/request-quote.html

Regional Insights
Europe leads the global bioreactors market by revenue share, a position anchored by its concentration of large-scale biomanufacturing plants and long-standing industrial infrastructure for pharmaceutical production. North America and Europe together account for approximately 60% of total market share, with the United States hosting the highest count of bioprocessing facilities globally.

Asia-Pacific is the fastest-expanding region in terms of new biomanufacturing facility count, and it already hosts 122 bioreactor manufacturers, the highest concentration globally. China, South Korea, and India are all scaling capacity, though average plant sizes remain smaller than their Western counterparts for now. As those facilities mature and capital deployment increases, the Asia-Pacific region's share of global bioreactor revenues will rise considerably through 2035.

Competitive Landscape
The bioreactors market features approximately 250 active manufacturers worldwide, ranging from global life sciences equipment leaders to specialized regional producers. Key players profiled in the Roots Analysis report include Applikon Biotechnology, Bionet, Cytiva, Eppendorf, Merck, Ollital Technology, Parr Instrument Company, Sartorius, Shanghai Bailun Biological Technology, Solaris Biotech, Solida Biotech, and Zhengzhou Laboao Instrument Equipment (LABAO).

Start-ups constitute 54% of all players in the market, a proportion that reflects active venture investment in next-generation bioreactor designs, AI-assisted bioprocess optimization, and sustainable manufacturing alternatives. The main competitive battlegrounds are automation capability, scalability across batch sizes, compatibility with continuous processing, and the ability to service the specific needs of cell and gene therapy manufacturers. With consolidation activity picking up, as seen in Tetra Pak's December 2025 acquisition of Bioreactors.net, larger players are moving to broaden their bioprocessing portfolios through targeted M&A.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/bioreactors-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.